Sirolimus coated stents are a promising new therapy for restenosis in de-novo coronary lesions. Except for the promising results achieved with brachytherapy, the treatment of recurrent in-stent-restenosis (ISR) remains a challenging clinical issue. Given the efficacy of systemic administration of Sirolimus to prevent neointimal hyperplasia in animal models and to halt and even reverse the progression of allograft vasculopathy, it seems reasonable to consider this drug as a good option for oral treatment to prevent recurrent ISR. This randomized, double-blind, placebo-controlled study is aimed at evaluating the efficacy of 2 different regimens of oral Sirolimus in patients with ISR treated with repeat PTCA. We enrolled 300 patients with ISR in native coronary arteries who were randomly assigned to one of three treatment arms: usual-dose Sirolimus, high-dose Sirolimus and placebo. All patients in the two treatment arms received Sirolimus loading two days prior to and the day of intervention followed by maintenance therapy for 7 days. The difference between usual-and high-dose arms was in the amount of pre-treatment, 8 mg in the usual-dose Sirolimus arm and 24 mg in the high-dose Sirolimus arm. The maintenance therapy after intervention consisted of 2mg/d for 7 days in both arms. Angiographic binary restenosis at 6-months angiography was the primary end point of the study. Sample size was estimated to give sufficient power to the trial for detecting a 25 and 50% reduction of the binary restenosis with the two Sirolimus doses. Angiographic and 1-year clinical follow-up is in progress and will be completed in January 2004. The final study results will be presented. Conclusions: Stent thrombosis was infrequent in radiation failure patients receiving sirolimus stents. At 6 month follow-up, target lesion revascularization in radiation failure patients receiving sirolimus stents is low, and similar to non-radiation failure patients. Sirolimus stents are a safe and effective treatment for vascular radiation failure.
Sirolimus coated stents are a promising new therapy for restenosis in de-novo coronary lesions. Except for the promising results achieved with brachytherapy, the treatment of recurrent in-stent-restenosis (ISR) remains a challenging clinical issue. Given the efficacy of systemic administration of Sirolimus to prevent neointimal hyperplasia in animal models and to halt and even reverse the progression of allograft vasculopathy, it seems reasonable to consider this drug as a good option for oral treatment to prevent recurrent ISR. This randomized, double-blind, placebo-controlled study is aimed at evaluating the efficacy of 2 different regimens of oral Sirolimus in patients with ISR treated with repeat PTCA. We enrolled 300 patients with ISR in native coronary arteries who were randomly assigned to one of three treatment arms: usual-dose Sirolimus, high-dose Sirolimus and placebo. All patients in the two treatment arms received Sirolimus loading two days prior to and the day of intervention followed by maintenance therapy for 7 days. The difference between usual-and high-dose arms was in the amount of pre-treatment, 8 mg in the usual-dose Sirolimus arm and 24 mg in the high-dose Sirolimus arm. The maintenance therapy after intervention consisted of 2mg/d for 7 days in both arms. Angiographic binary restenosis at 6-months angiography was the primary end point of the study. Sample size was estimated to give sufficient power to the trial for detecting a 25 and 50% reduction of the binary restenosis with the two Sirolimus doses. Angiographic and 1-year clinical follow-up is in progress and will be completed in January 2004. The final study results will be presented. Background -Little is known about the vascular effects of drug-eluting stents in patients with ISR who already failed radiation therapy and bypass surgery. The aim of this study was to determine the vascular effects of SES in patients enrolled in the SECURE trial using 3D volumetric intravascular ultrasound. Methods: The compassionate use of SES (SECURE) trial was conducted in 5 clinical US sites. All patients with failed brachytherapy had scheduled 8 month IVUS follow-up. Volumetric 3D IVUS data was analyzed by an independent core lab. Methods and Results -252 patients have been enrolled in the SECURE trial. So far, 39 patients have completed 8-month IVUS follow-up. Mean age was 60 y, 66% were male, 78% had previous CABG, 35% were diabetics and 16% had SVG lesions. On average, 1.38 stents/lesion were implanted. Mean stented segment length was 27.4mm. Overall, lumen volume after 8-months was 155mm 3 and there was 10.1% intimal hyperplasia. Minimal lumen CSA was 4.14mm 2 . Eleven patients had >50% lumen obstruction by IVUS. There was no stent malapposition or aneurysm formation at follow-up. Only one patient showed positive vessel remodeling at follow-up. Matched baseline and follow-up data (table) . Conclusion -The use of SES in patients with previous radiation therapy was not associated with stent malapposition or significant vessel remodeling or aneurysm formation. The IH volume after SES was minimal and compares favorably with that observed in a much lower risk population treated with bare stents. 
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